Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ACURA PHARMACEUTICALS, INC (ACUR)
|
Add to portfolio |
|
|
|
| Price: |
$0.52
| | Metrics |
| OS: |
66.0
|
M
| |
|
|
| Market cap: |
$34.3
|
M
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$34.3
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 1.6 | 3.6 | 2.7 | 0.4 | 3.0 | 4.5 | 8.6 | 0.8 |
| Revenue growth | -56.2% | 34.4% | 548.0% | -86.2% | -33.6% | -48.0% | 1043.4% | 510.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.5 | 0.7 | 0.2 |
| Gross profit | 1.6 | 3.6 | 2.7 | 0.4 | 2.8 | 4.0 | 7.9 | 0.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.7% | 89.9% | 92.4% | 69.8% |
| Selling, general and administrative | 1.3 | 2.5 | 1.9 | 2.6 | 4.3 | 6.5 | 9.0 | 7.9 |
| Research and development | 1.5 | 1.8 | 1.5 | 1.8 | 3.7 | 4.0 | 2.6 | 4.6 |
| EBITA | -1.2 | -0.7 | -0.5 | -3.7 | -5.0 | -6.4 | -3.8 | -12.0 |
| EBITA margin | -76.0% | -19.3% | -19.5% | -904.4% | -169.2% | -142.2% | -44.2% | -1603.7% |
| Amortization of intangibles | 0.0 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| EBIT | -1.2 | -0.8 | -0.7 | -3.9 | -5.2 | -6.6 | -4.0 | -12.2 |
| EBIT margin | -77.7% | -21.2% | -27.3% | -954.9% | -176.2% | -146.9% | -46.6% | -1624.4% |
| Pre-tax income | -0.9 | -1.2 | -3.8 | -3.8 | -5.8 | -7.4 | -5.0 | -13.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% | 0.0% | 0.0% | 0.0% |
| Net income | -0.9 | -1.2 | -3.8 | -3.8 | -5.7 | -7.4 | -5.0 | -13.2 |
| Net margin | -56.2% | -33.8% | -142.0% | -937.1% | -191.6% | -165.5% | -58.1% | -1758.9% |
| |
| Diluted EPS | ($0.02) | ($0.04) | ($0.14) | ($0.18) | ($0.36) | ($0.62) | ($0.46) | ($1.35) |
| Shares outstanding (diluted) | 56.8 | 32.3 | 26.7 | 21.1 | 15.9 | 11.9 | 10.8 | 9.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|